- RCPT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $60.3 million.
- RCPT is down 2.1% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in RCPT with the Ticky from Trade-Ideas. See the FREE profile for RCPT NOW at Trade-Ideas More details on RCPT: Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics for immune disorders. Currently there are 3 analysts that rate Receptos a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Receptos has been 581,700 shares per day over the past 30 days. Receptos has a market cap of $3.1 billion and is part of the health care sector and drugs industry. Shares are up 267.5% year-to-date as of the close of trading on Friday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Receptos as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share and deteriorating net income.